Continuous Innovation:

The Value of Post-Approval R&D



July 2026

AUTHORS

This paper was authored by **Mark Schultz**, The IP Policy Institute, The University of Akron (IPPI), and **Jennifer Brant**, Innovation Insights, with **Douglas Park**, IPPI.

The graphic design and layout are by Dilucidar.

> *Continuous innovation delivers great value to patients and society.*

What happens after a drug is approved often matters as much as, or more than, the approval itself. Biopharmaceutical companies continue innovating, seeking to expand the use of the drug to new patient populations and different diseases, develop better delivery systems, and improve formulations.

This ongoing work, known as *continuous innovation*, is a defining feature of the biopharmaceutical industry. It often builds on earlier research, but becomes feasible and clinically actionable after a medicine has been approved for use in patients by regulators such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA).

Continuous innovation delivers great value to patients and society. For many of today's medicines, innovation resulting from post-approval research and development accounts for roughly twice as much patient use as the original approved indication.[1] In some therapeutic areas, half of all treatment options originated not from new molecules but from continued research on existing ones.[2]

In oncology, post-approval indication expansion is the norm: two-thirds of cancer drugs approved over the past decade later gained at least one additional indication.[3] This research tends to expand treatment to earlier lines of therapy, when outcomes are typically better. Among cancer drugs that gained new line-of-therapy approvals, 93% moved from later lines to earlier lines.[4]

A common question is why the initial version of a medicine is not already optimized in every respect. The answer lies in how science progresses. The medicine that reaches approval reflects the best that current knowledge and technology allow at that time.

1 Employee Benefit Research Institute. (2025). What employers should know about the Inflation Reduction Act and drug development. https://www.ebri.org/docs/default-source/fast-facts(public)/ff-529-inflationreductionact-1may25.pdf?sfvrsn=27d8042f_1 (finding "that small-molecule drugs used to treat conditions related to oncology, cardiology, and immunology were used to treat patients with a follow-on indication about twice as often as for the initial indication.").

2 Partnership for Health Analytic Research. (2023). Implications of the Inflation Reduction Act Price Setting Provisions on Post-approval Indications for Small Molecule Medicines. https://advi.com/wp-content/uploads/2024/12/Implications-of-the-IRA-on-Post-Approval-Small-Molecules-2006-2012_Final.pdf

3 Patterson, J. A., Motyka, J., Salih, R., Nordyke, R., O'Brien, J. M., & Campbell, J. D. (2025). Subsequent indications in oncology drugs: Pathways, timelines, and the Inflation Reduction Act. *Therapeutic Innovation & Regulatory Science, 59*, 102–111. https://doi.org/10.1007/s43441-024-00706-6

4 Ibid.

Approval opens new possibilities, however, as science advances, use in everyday care reveals practical challenges and unmet needs, and clinical experience highlights opportunities to deliver greater value to patients and healthcare systems. Once a medicine has been shown to be safe and effective, it becomes a proven and powerful foundation for further research and discovery.

This ongoing work is neither inevitable nor guaranteed to succeed. Each improvement requires additional research and development, which takes investment and carries risk. New science may enable a better delivery route, or it may not. A promising combination therapy may prove safe and effective in trials, or it may fail.

Once developed, these improvements succeed in practice only if they are accepted by a range of gatekeepers: clinicians, healthcare systems, insurers, regulators, public payers, and patients themselves. When they do succeed, they can expand access to new patient populations, improve ease of use and adherence, and reduce burdens on healthcare delivery.

> *The opportunity to patent new and useful improvements helps secure and encourage the investments necessary to support post-approval research and development.*

Post-approval inventions that solve real problems may be patentable. These patents reflect new work, not extensions of old protections. Most important, the opportunity to patent new and useful improvements helps secure and encourage the investments necessary to support post-approval research and development.

The case studies that follow show how continuous innovation works and the investment in new research and development it requires. In this series, we examine three of the most important forms of continuous innovation:

- **New indications:** expanding the use of proven medicines to treat new diseases and patient populations.
- **Delivery systems:** improving how medicines are administered to make treatment easier and more accessible.
- **Combination therapies:** developing validated regimens that combine medicines to improve outcomes and simplify care.

Each section provides concrete examples illustrating what this work involves and why it matters.

NEW INDICATIONS

Expanding the use of proven medicines to treat new diseases and patient populations



> *A therapy developed for one condition may come to play an important role across multiple diseases, often improving outcomes for far more patients than originally anticipated.*

Some of the most significant advances in medicine occur not when a new drug is first approved, but when an existing medicine is shown to benefit entirely new groups of patients. Over time, a therapy developed for one condition may come to play an important role across multiple diseases, often improving outcomes for far more patients than originally anticipated.

In biopharmaceuticals, this process is a key form of *continuous innovation*, the ongoing effort to build on existing medicines through additional research to expand how they are used in practice. One important dimension of this work is the development of new indications.[1]

What is a "new indication"?

A new indication is a separate regulatory approval allowing a medicine to be used to treat a different disease, condition, stage of illness, or patient population than originally authorized.

Even when the underlying molecule remains the same, each indication answers a distinct clinical question and provides a novel answer. Demonstrating that a medicine works in a new setting requires evidence that it improves meaningful health outcomes for a different disease, stage of disease, condition, or patient population under appropriate dosing and safety conditions.

Why does new-indication innovation occur after approval?

Drug development is inherently uncertain and resource intensive. Most drug candidates fail during clinical testing, and success depends on identifying a disease area where scientific evidence suggests the strongest likelihood of demonstrating safety and effectiveness.

For that reason, initial development efforts typically focus on a single indication where unmet need is clearest and the probability of success is highest. Securing approval for that first use is a critical milestone.

Once a medicine has been shown to be safe and effective, it provides a proven foundation for further research. Scientists can then explore whether the same therapy may benefit other diseases or patient populations. These opportunities often emerge from scientific insights gained during development or from clinical experience after approval.

Researchers may identify shared biological pathways across diseases, observe unexpected benefits in certain patient groups, or recognize that an existing therapy could address related health challenges.

While researchers identify potential opportunities, the outcomes are never certain. Researching these hypotheses carries the real risk of failure and the loss of substantial investments. A drug that works in one condition or patient population may not work in another or may require additional innovation to do so safely and effectively.

Moving from hypothesis to approval requires new clinical trials. These studies often involve different patient populations, different endpoints, and different safety considerations. In many cases, large trials are needed to demonstrate meaningful clinical benefit in the new setting.

This staged approach allows patients to gain timely access to promising therapies while enabling further advances as new evidence emerges. It also allows society to derive greater value from medicines that have already been shown to work.

Post-approval development of new indications can:

- Expand access to patients who previously had limited or no effective treatment options;
- Improve outcomes in related or overlapping disease states; and
- Extend the benefits of a proven therapy to broader populations.

Case Study: Jardiance – From Glucose Control to Cardiovascular and Kidney Protection

Jardiance (empagliflozin) began as a blood-sugar medication for type 2 diabetes developed by Boehringer Ingelheim and co-developed and co-marketed with Eli Lilly. It is now widely used not only to improve glycemic control, but also to reduce the risk of cardiovascular death, decrease hospitalization for heart failure, and slow the progression of chronic kidney disease. That transformation required years of additional research and large-scale clinical trials conducted after the drug's initial approval.

Jardiance was approved by the U.S. Food and Drug Administration in 2014 as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. At that time, its approved use was limited to lowering blood sugar.

Patients with type 2 diabetes face high rates of cardiovascular disease, heart failure, and kidney decline. Historically, lowering blood sugar alone did not prevent these outcomes. Earlier diabetes medications had regularly shown neutral or even adverse cardiovascular effects in dedicated outcome trials. Regulators therefore recommended new cardiovascular outcomes studies to demonstrate cardiovascular safety.

The EMPA-REG OUTCOME trial enrolled more than 7,000 adults with type 2 diabetes and established cardiovascular disease.[2] Conceived originally as a safety trial for cardiovascular events, it was subsequently amended to add further layers of statistical analysis and to test whether empagliflozin reduced major adverse cardiovascular events compared with placebo added to standard care. Beyond safety, the trial unexpectedly demonstrated a significant reduction in the composite primary endpoint, with particularly notable reductions in cardiovascular death and hospitalization for heart failure. In 2016, the FDA approved a new indication allowing Jardiance to be used to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease.

Jardiance was later also evaluated in clinical trials for symptomatic heart failure, including for individuals without diabetes. These studies demonstrated significant reductions in heart-failure hospitalizations, leading to regulatory approvals that extended its use to a much broader patient population.

Further research, including the EMPA-KIDNEY trial, then examined whether empagliflozin slowed progression of chronic kidney disease, again including many patients without diabetes.[3] That study showed a significant reduction in the composite outcome of kidney disease

> *Without post-approval investment in further research and innovation, Jardiance might have remained solely a glucose-lowering drug. Instead, it evolved into a medicine used across cardiology, nephrology, and endocrinology.*

progression or cardiovascular death. Regulatory authorities subsequently expanded the drug's indications to include chronic kidney disease in appropriate patient populations.

Each of these therapeutic innovations was based on unexpected findings not previously observed with other classes of antidiabetics and required extensive clinical trials with different patient groups and endpoints. Demonstrating glucose lowering did not establish that the medicine would reduce cardiovascular mortality or delay kidney failure. Those benefits had to be independently demonstrated.

As a result of sustained post-approval research, Jardiance evolved from a glucose-lowering therapy into a medicine used across cardiology, nephrology, and endocrinology. Clinical guidelines now recommend SGLT2 inhibitors such as empagliflozin not only for glycemic control but also to reduce heart-failure hospitalization, cardiovascular death, and progression of kidney disease in appropriate patients.

Case Study: Eylea – Expanding Vision Protection Across Retinal Diseases

Eylea (aflibercept) began as a treatment for vision loss from wet age-related macular degeneration. It is now widely used to prevent vision loss across multiple retinal diseases, including retinal vein occlusion and diabetic eye disease affecting working-age adults. These expansions required separate clinical trials in distinct patient populations and were not assumed at the time of initial approval.

Eylea was approved in 2011 for neovascular (wet) age-related macular degeneration, a leading cause of severe vision loss in older adults. The drug works by inhibiting vascular endothelial growth factor (VEGF), which drives abnormal blood vessel growth in the retina.

Researchers hypothesized that Eylea might preserve vision in other retinal diseases, but determining whether it would do so required addressing distinct biological, clinical, and regulatory challenges. These conditions differ significantly in cause and patient population. Central retinal vein occlusion involves acute vascular blockage, while diabetic macular edema results from chronic metabolic damage to retinal blood vessels in patients with diabetes.

Because of these differences, it was not known whether Eylea's benefits in wet AMD would translate to these other conditions.

Clinical trials demonstrated that aflibercept improved visual outcomes in patients with macular edema following retinal vein occlusion and in patients with diabetic macular edema. These results supported additional FDA approvals in 2012 and 2014, followed by further expansion to diabetic retinopathy in 2015.[4]

These advances addressed important unmet needs. While wet AMD primarily affects older adults, diabetic eye disease and retinal vein occlusion can cause severe vision loss in younger and working-age individuals, with significant personal and economic consequences.

Each additional indication required disease-specific trials evaluating visual acuity, dosing, and safety in distinct patient populations. Success in one condition did not

establish effectiveness in another. These questions had to be tested directly.

As a result of continued research, Eylea evolved from a treatment for a single condition into a widely used therapy across multiple major causes of vision loss.

Are new-indication expansions trivial?

The case studies above illustrate that expanding a medicine to new uses is not a matter of simple extrapolation but requires substantial additional research. Each new indication involves developing and testing a scientific hypothesis, addressing technical challenges, conducting clinical trials, and demonstrating meaningful benefit in a new patient population. A treatment that is effective in one condition may not work in another, or may require different dosing, monitoring, or patient selection.

For patients, these expansions frequently provide essential new options. For example, in the past decade, roughly two-thirds of cancer drugs gained at least one additional approved use beyond their original indication.[5]

> *Patents on new indications do not prevent generic manufacturers from marketing the medicine for its original approved uses once the relevant patents expire.*

Why are there later-filed patents on new indications? Do they block competition?

Because research on new indications occurs after a medicine has been approved, any resulting inventions are developed later in time. This work involves addressing new scientific and clinical questions, such as whether a medicine is effective in a different disease, how it should be used in a new patient population, and how its safety profile changes in that setting.

When these questions are answered through additional research, the resulting discoveries may be patentable. These patents reflect new inventions arising from further study, not extensions of earlier protections.

Patents on new indications do not prevent generic manufacturers from marketing the medicine for its original approved uses once the relevant patents expire. In the United States, generics can choose to enter the market by relying on "skinny labels" that exclude patented uses, allowing competition for unpatented indications while new uses remain protected. For a more detailed discussion of how post-approval patents relate to competition and generic entry, see our companion papers on evergreening and patent thickets.

Endnotes

1 This paper draws on desk research and interviews with scientific, regulatory, and IP teams at innovative biopharmaceutical companies. For product case studies, the timelines and scientific descriptions reflect publicly documented information, supplemented in some cases by interview context. Factual claims about approval dates, indications, and regulatory requirements were verified against publicly available FDA and EMA records. Information on clinical trials (including enrollment and outcomes) was checked through ClinicalTrials.gov entries and published trial results where available.

2 Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., Broedl, U. C., Inzucchi, S. E., & EMPA-REG OUTCOME Investigators (2015). Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. *The New England Journal of Medicine*, 373(22), 2117–2128. https://doi.org/10.1056/NEJMoa1504720

3 The EMPA-KIDNEY Collaborative Group, Herrington, W. G., Staplin, N., Wanner, C., Green, J. B., Hauske, S. J., Emberson, J. R., Preiss, D., Judge, P., Mayne, K. J., Ng, S. Y. A., Sammons, E., Zhu, D., Hill, M., Stevens, W., Wallendszus, K., Brenner, S., Cheung, A. K., Liu, Z. H., Li, J., … Haynes, R. (2023). Empagliflozin in Patients with Chronic Kidney Disease. *The New England Journal of Medicine*, 388(2), 117–127. https://doi.org/10.1056/NEJMoa2204233

4 Garweg, J. G., Štefanickova, J., Hoyng, C., Niesen, T., Schmelter, T., Leal, S., Sivaprasad, S., & VIOLET Investigators (2022). Dosing Regimens of Intravitreal Aflibercept for Diabetic Macular Edema Beyond the First Year: VIOLET, a Prospective Randomized Trial. *Advances in Therapy*, 39(6), 2701–2716. https://doi.org/10.1007/s12325-022-02119-z; Mitchell, P., McAllister, I., Larsen, M., Staurenghi, G., Korobelnik, J. F., Boyer, D. S., Do, D. V., Brown, D. M., Katz, T. A., Berliner, A., Vitti, R., Zeitz, O., Metzig, C., Lu, C., & Holz, F. G. (2018). Evaluating the Impact of Intravitreal Aflibercept on Diabetic Retinopathy Progression in the VIVID-DME and VISTA-DME Studies. *Ophthalmology Retina*, 2(10), 988–996. https://doi.org/10.1016/j.oret.2018.02.011

5 Patterson, J. A., Motyka, J., Salih, R., Nordyke, R., O'Brien, J. M., & Campbell, J. D. (2025). Subsequent Indications in Oncology Drugs: Pathways, Timelines, and the Inflation Reduction Act. *Therapeutic Innovation & Regulatory Science, 59*, 102–111. https://doi.org/10.1007/s43441-024-00706-6

DELIVERY SYSTEMS

Improving how medicines are administered to make treatment easier and more accessible



> *Improvements in delivery can make treatment easier to use, reduce burden on patients, improve adherence to treatment plans, and allow care to shift from hospitals to outpatient or home settings.*

How a medicine is delivered can be as important to successful treatment as the medicine itself. Improvements in delivery can make treatments easier to use, expand access to new patients, and reduce burdens on healthcare systems. For many therapies, advances in delivery have played a central role in improving patient outcomes.

In biopharmaceuticals, this kind of ongoing improvement is often referred to as *continuous innovation*, the process of building on an approved medicine through additional research to enhance how it works in practice. One important form of continuous innovation focuses on how a medicine is delivered.[1]

Improvements in delivery can make treatment easier to use, reduce burden on patients, improve adherence to treatment plans, and allow care to shift from hospitals to outpatient or home settings. Even when the underlying active ingredient remains the same, improving how it is delivered may require substantial reformulation, new delivery devices, and additional clinical validation.

What is a drug "delivery system"?

A drug's delivery system is the method of getting the drug into the patient's body. While oral pills remain common, modern medicines are delivered in many ways, including injections, infusions, patches, inhalers, and on-body devices.

Each delivery method involves distinct scientific and clinical tradeoffs. A pill may be easy to take but require frequent dosing; an injectable may reduce dosing frequency but require careful formulation and administration; a patch may be more convenient but is generally more challenging to develop.

Improving delivery systems often requires solving complex scientific and engineering challenges.

Why does delivery-system innovation occur after approval?

The delivery system used at approval reflects what science and technology make possible at that time. Innovators begin with the safest and most effective delivery method based on existing knowledge.

After approval, new opportunities for improvement emerge. Scientific advances may enable new delivery approaches. Patients' everyday experience may reveal challenges with dosing, administration, or patient adherence. These insights create opportunities to improve how a medicine is delivered and used in practice.

Developing improved delivery systems is neither simple nor inevitable. Some medicines can only be safely delivered in certain ways. Others may require years of additional research to enable a new delivery route.

Innovators also prioritize bringing promising medicines to patients as quickly as possible, particularly for serious or life-threatening conditions. Once a drug enters late-stage clinical trials, its form and delivery system generally remain fixed through regulatory approval. Improvements are therefore often pursued after approval, when further research becomes practicable.

After approval, scientists can carry out additional R&D to improve delivery systems as new technologies and insights emerge. This multi-stage approach allows patients to gain timely access to effective treatments while enabling later improvements based on additional evidence.

Post-approval delivery innovation can:

- Make treatment easier or less burdensome for patients;
- Expand access to patients who cannot tolerate earlier forms; and
- Reduce demands on hospitals and healthcare staff.

Because changes in delivery can affect dosing, safety, and outcomes, delivery innovations must be supported by additional research and clinical evidence to demonstrate safety, effectiveness, and value in practice. These improvements often require significant investment, including additional clinical studies, which are typically large and costly trials, to validate how the new delivery method performs in practice.

Case Study: Neupogen → Neulasta → Neulasta Onpro

Amgen's Neupogen (filgrastim) and its successors illustrate how delivery-system innovation can meaningfully improve patient experience and outcomes through sustained post-approval research.

Neupogen was approved by the U.S. Food and Drug Administration (FDA) in 1991 to treat chemotherapy-induced neutropenia, a dangerous reduction in white blood cells that increases the risk of serious infection. Beyond its initial use in cancer patients receiving myelosuppressive chemotherapy, Neupogen's indications later expanded to include patients undergoing bone-marrow transplantation, those with severe congenital neutropenia, aplastic anemia, myelodysplastic syndromes, and certain patients with HIV/AIDS. Across these settings, Neupogen played a critical role in reducing infection risk and enabling patients to remain on life-saving therapies.

Despite its clinical importance, Neupogen imposed a significant treatment burden. Patients typically required frequent injections or infusions. For example, following chemotherapy it needed to be administered daily for several days.

Once the drug's core therapeutic value was established, scientists were able to focus on improving how it could be delivered in practice.

Amgen addressed this challenge through the development of Neulasta (pegfilgrastim). By attaching a polyethylene glycol (PEG) moiety to filgrastim, scientists extended the drug's half-life, allowing it to remain in the body longer while preserving its biological function.[2] Approved in 2002, Neulasta reduced dosing from daily injections to a single dose per chemotherapy cycle. This long-acting formulation substantially improved convenience and adherence for patients and was rapidly adopted in clinical practice, reflecting its clear value.

Delivery innovation continued with the introduction of the Neulasta Onpro on-body injector, a wearable drug-delivery device approved for use in the U.S. in 2015 and Europe in 2018. Applied to the patient's skin on the same day as chemotherapy, the device automatically delivers Neulasta approximately 27 hours later, at the clinically optimal time. This innovation eliminated the need for patients to return to a clinic the following day for an injection—an especially meaningful benefit for patients already coping with the physical and logistical burdens of cancer treatment.

The Onpro system required more than incremental change. It combined drug formulation, device engineering, timing precision, and clinical validation into a single integrated product. In practice, it allowed patients greater independence while also improving care coordination for clinicians. Observational studies have shown high reliability in drug delivery, and the device has been widely adopted in clinical practice, underscoring its practical importance.[3]

The evolution from Neupogen to Neulasta and then to Neulasta Onpro demonstrates that delivery-system innovation is not trivial for innovators or patients. Each step required substantial research and development, as well as additional clinical studies to demonstrate safety, effectiveness, and performance in practice. For patients and clinicians, these improvements reduced treatment burden, improved adherence, and made treatment more manageable, while preserving the drug's core therapeutic benefit. These post-approval innovations delivered tangible value for patients and healthcare systems alike.

Case Study: Keytruda (Infusion to Subcutaneous Injection)

Keytruda (pembrolizumab), developed by Merck & Co., Inc. (USA) (MSD), illustrates how delivery-system innovation for a complex biologic can meaningfully improve patient experience, healthcare efficiency, and access without altering the drug's underlying therapeutic mechanism.

Keytruda was initially approved as an immune checkpoint inhibitor for the treatment of melanoma and administered by slow infusion into the bloodstream in hospitals or specialized clinics. This method of delivery typically required prolonged chair time, dedicated infusion facilities, and trained clinical staff. As use of the drug expanded to additional cancer types, these demands placed increasing time and resource burdens on patients and healthcare systems.

After initial approval, advances in formulation science created an opportunity to develop a new delivery option: a formulation that could be administered by injection under the skin. This change was technically demanding.[4] The drug had to be reformulated so that a large, complex molecule infused slowly into the bloodstream could be delivered in a much smaller volume under the skin, absorbed reliably, and remain safe and effective. Addressing challenges related to concentration, stability, dosing, and absorption required substantial scientific problem-solving, and success was not assured.

The resulting subcutaneous delivery system substantially reduced the time required for treatment and enabled care to take place in a wider range of clinical settings. For patients, this reduced the disruption associated with lengthy infusion visits. For healthcare providers, it freed infusion capacity and staff time, improving system efficiency.

Where treatment is delivered can also affect access. Receiving care in a local doctor's office rather than a distant infusion center may determine whether a patient can realistically receive treatment at all, particularly when transportation options are limited or when repeated, lengthy visits are impractical.

The post-approval innovation to Keytruda demonstrates that delivery-system improvements for biologics are neither trivial nor automatic. Reformulating an established medicine for a new route of administration requires sustained research, technical expertise, and clinical validation. In the case of Keytruda, delivery-system innovation improved convenience and access while preserving the drug's core therapeutic benefit.

Are changes to delivery systems trivial?

These case studies illustrate that improvements in how medicines are delivered are not simple changes in form. Developing a new delivery system often requires reformulating the medicine so it can be absorbed and distributed properly through a different route of administration, designing devices or delivery mechanisms that reliably administer the correct dose, and ensuring that the medicine remains stable and effective in its new form.

“Where treatment is delivered can also affect access. Receiving care in a local doctor's office rather than a distant infusion center may determine whether a patient can realistically receive treatment at all.”

> *For patients, improved delivery systems can make treatment easier to follow, reduce discomfort, expand access by moving treatment to more convenient settings, and increase treatment options for those who cannot tolerate earlier forms.*

These changes can alter how a medicine behaves in the body and how patients use it in practice, requiring additional clinical studies to confirm safety, dosing, and performance in real-world settings.

The resulting improvements are also not trivial for patients or healthcare providers. For patients, improved delivery systems can make treatment easier to follow, reduce discomfort, expand access by moving treatment to more convenient settings, and increase treatment options for those who cannot tolerate earlier forms. For healthcare systems, they can shift care to outpatient or home settings and reduce demands on clinical staff.

Why are there later-filed patents on new delivery systems? Do they block competition?

Delivery-system innovations typically occur years after a drug's initial approval, reflecting the additional time and research required to identify challenges, develop solutions, and validate changes. That work often involves solving new technical problems, such as reformulating a drug for a different route of administration, designing delivery devices, or ensuring consistent dosing and performance outside controlled clinical settings.

When these challenges are successfully addressed, the resulting solutions may be patentable. These patents reflect new inventions arising from additional research, not extensions of earlier protections.

Patents on delivery-system improvements do not prevent generic or biosimilar manufacturers from entering the market using the original delivery method once relevant patents expire. Generic manufacturers can offer the drug in the original form, while improved delivery systems compete based on demonstrated clinical value, convenience, and patient preference. A fuller discussion of how post-approval patents interact with generic entry is provided in our companion paper on evergreening and thickets claims.

Endnotes

1 This paper draws on desk research and interviews with scientific, regulatory, and IP teams at innovative biopharmaceutical companies. For product case studies, the timelines and scientific descriptions reflect publicly documented information, supplemented in some cases by interview context. Factual claims about approval dates, indications, and regulatory requirements were verified against publicly available FDA and EMA records. Information on clinical trials (including enrollment and outcomes) was checked through ClinicalTrials.gov entries and published trial results where available.

2 Molineux, G. (2003). Pegfilgrastim: Using Pegylation Technology to Improve Neutropenia Support in Cancer Patients. *Anti-Cancer Drugs,* 14(4), 259–264. https://doi.org/10.1097/00001813-200304000-00002

3 Sandschafer, D., et al. (2022). MT17 Assessment of Device Failures and Medication Errors with the Pegfilgrastim On-body Injector in the US and EU. *Value in Health,* 25(7), S535. https://doi.org/10.1016/j.jval.2022.04.1296

4 In Brief: Keytruda Qlex - A Subcutaneous Formulation of Pembrolizumab. (2025). *The Medical Letter on Drugs and Therapeutics,* 67(1741), e184. https://doi.org/10.58347/tml.2025.1741f

COMBINATION THERAPIES

Developing new products to improve outcomes and simplify care



> *A combination therapy is not simply a matter of adding drugs together. It requires integrating previously developed medicines into a new product so that they can be used safely and effectively together.*

Many of the most effective treatments in modern medicine do not rely on a single drug, but on carefully developed combinations of medicines. These combinations can improve outcomes, reduce side effects, and make complex treatment regimens easier for patients to follow.[1]

In biopharmaceuticals, developing such combinations is an important form of ***continuous innovation,*** the process of building on existing medicines through additional research to improve how they work in practice. A combination therapy is not simply a matter of adding drugs together. It requires integrating previously developed medicines into a new product so that they can be used safely and effectively together in practice. The resulting product may differ from the earlier, individual products, for example by using different doses or requiring new formulations or delivery approaches to achieve safe and effective use.

What is a combination therapy?

A combination therapy brings two or more medicines together into a new, single, validated therapeutic product that has been shown to perform safely and effectively as a combined intervention. In some cases, this takes the form of a fixed-dose combination tablet that delivers multiple drugs in one pill. In other cases, it involves a defined regimen supported by clinical evidence.

Combination therapies differ from informal co-prescribing: they require research and innovation to determine whether medicines interact safely, reinforce each other's benefits, or introduce new risks when used together. The goal is not only convenience but also improved clinical outcomes and more reliable treatment in practice. Once validated, a combination therapy is treated clinically and regulatorily as a distinct therapeutic intervention—a new product that is not simply the sum of its component medicines. It is evaluated, approved, and used based on its performance as a combined therapy.

Why does combination-therapy innovation often occur after approval?

Combination therapies are often explored after individual medicines have already been approved. Once a drug has been shown to be safe and effective on its own, it becomes possible to study how it may work in combination with other therapies.

At that point, scientific and clinical opportunities emerge. Researchers may identify complementary biological mechanisms, observe patterns in clinical use, or recognize that combining therapies could improve outcomes or simplify treatment. These insights create a foundation for developing validated combination regimens.

This work is neither routine nor guaranteed to succeed. A combination that appears promising in theory may prove ineffective or unsafe in practice. Determining how medicines interact, identifying appropriate dose combinations, and evaluating safety and efficacy in different patient populations all require substantial additional research.

Post-approval experience can also reveal unmet needs, such as when patients continue to experience incomplete symptom control or struggle to manage multiple medicines on complex schedules. Understanding these practical challenges often motivates further research into combination therapies that are both clinically effective and easier to use.

Post-approval development of combination therapies can:

- Improve outcomes through complementary or synergistic effects among medicines;
- Reduce side effects or complications by balancing mechanisms of action;
- Simplify treatment by reducing the number of pills or dosing complexity; and
- Expand access for patients who may not tolerate or adhere to more complex regimens.

Because combining medicines can affect dosing, safety, and outcomes, combination therapies must be supported by additional research and clinical evidence to demonstrate safety, effectiveness, and value in practice. These efforts often require significant investment, including large clinical studies to validate how the combination performs in practice.

Case Study: Atripla Combination HIV Treatment

Atripla, a landmark combination antiretroviral therapy introduced in 2006, illustrates how validated combination therapies can improve outcomes for patients by addressing real-world treatment challenges that single drugs or informal co-prescribing could not reliably solve.

“*Because combining medicines can affect dosing, safety, and outcomes, combination therapies must be supported by additional research and clinical evidence to demonstrate safety, effectiveness, and value in practice.*”

Before modern combination regimens, HIV treatment was complex and difficult for patients to sustain. Patients often took multiple antiretroviral medicines at different times of day, sometimes with dietary restrictions. Strictly adhering to this dosing schedule over many years was challenging. Even occasional missed doses could allow the virus to develop resistance and lead to treatment failure.

Atripla was the first widely used, complete, once-daily single-tablet regimen containing three active antiretroviral drugs: efavirenz, emtricitabine, and tenofovir disoproxil fumarate. The U.S. Food and Drug Administration (FDA) called its approval a "watershed moment" in the treatment of HIV.[2] By simplifying treatment to a single daily pill, Atripla made long-term adherence more feasible and helped transform HIV into a manageable chronic condition for many patients.

Although each component had been approved individually, developing a fixed-dose single-tablet combination required substantial additional research and development. Scientists had to ensure that all three medicines were absorbed at the correct levels and rates when taken together. This required careful formulation, bioequivalence studies, and evaluation of potential drug–drug interactions. Safety considerations also had to be assessed in the context of long-term use.

Clinical validation was essential. The underlying three-drug regimen had already been shown in pivotal trials to be highly effective compared with earlier standards of care. Building on that foundation, additional studies of the co-formulated tablet evaluated whether patients could safely maintain viral suppression when switching from multi-pill regimens.

Studies have shown that patients using single-tablet regimens tend to have higher adherence and better viral suppression than those on more complex regimens.[3] Some analyses also found that treatment failure on Atripla was associated with a longer time to virologic failure and less drug resistance than failure on comparable multi-pill regimens.[4]

The development of Atripla also illustrates the role of intellectual property in enabling post-approval innovation. Atripla was developed through collaboration between Gilead Sciences and Bristol Myers Squibb, with MSD involved in certain territories. No single company held rights to all three components. Each controlled patents and related intellectual property on different elements of the regimen.

These rights created both the incentive and the legal certainty needed to invest in developing a clinically validated combination product. They also enabled companies to share proprietary data and expertise to design, test, and commercialize the fixed-dose combination.

Over time, Atripla became a well-established part of HIV treatment and was widely described in clinical guidelines as a standard once-daily regimen for adults starting therapy. Its success helped pave the way for subsequent single-tablet regimens, demonstrating how post-approval combination innovation can deliver substantial benefits for patients and healthcare systems.

“IP rights created both the incentive and the legal certainty needed to invest in developing a clinically validated combination product.”

Case Study: Exforge Combination Hypertension Treatment

Many patients with high blood pressure require more than one medicine to achieve effective control. Exforge, developed and marketed by Novartis AG, illustrates how validated combination therapies can address this need by improving both clinical outcomes and treatment adherence.

In clinical practice, hypertension is often not adequately controlled with a single drug. Many patients require two medicines that act through different biological pathways, particularly when blood pressure is significantly elevated or when additional risk factors are present. Prescribing multiple drugs separately can increase pill burden and make long-term adherence more difficult.

Exforge, approved in 2007, combines amlodipine, a calcium-channel blocker, and valsartan, an angiotensin II receptor blocker, into a single once-daily tablet. These drugs act through complementary mechanisms: amlodipine relaxes blood vessels, while valsartan reduces vasoconstriction and fluid retention. Used together, they allow many patients to achieve effective blood-pressure control at moderate doses, rather than relying on higher doses of a single agent that may increase side effects.

Although these medicines had been prescribed together before Exforge, developing a fixed-dose combination required more than placing two drugs in a single package. Scientists had to identify dose combinations that reliably improved blood-pressure control across a broad range of patients while maintaining safety and tolerability.[5] This work required formulation development, bioequivalence testing, and dose-finding studies, all forms of innovation that were critical to the creation of the novel fixed-dose drug.

Randomized trials and subsequent clinical reviews showed that the combination produced greater reductions in blood pressure than either drug alone at comparable doses, including in patients whose hypertension was not adequately controlled on monotherapy. Studies of patients switched from single-agent therapies to the fixed-dose combination showed that many who had remained uncontrolled reached target blood-pressure levels after transition.

By simplifying treatment into a single daily pill, Exforge addressed a common gap in hypertension care. Evidence indicates that fixed-dose combinations can improve adherence and increase the proportion of patients who achieve blood-pressure targets compared with prescribing the same agents separately. Reflecting this evidence, treatment guidelines now recommend two-drug regimens, often delivered as single-tablet combinations, for many patients who are unlikely to achieve adequate control with monotherapy.

The development of Exforge also illustrates the role of intellectual property in enabling post-approval combination innovation. The fixed-dose product combined medicines originally developed by different companies under licensing and collaboration arrangements. These arrangements supported the

“This work required formulation development, bioequivalence testing, and dose-finding studies, all forms of innovation that were critical to the creation of the novel fixed-dose drug.”

investment and data sharing required to develop and bring a validated combination therapy to market.

Over time, Exforge and related fixed-dose combinations became well-established options in hypertension treatment, demonstrating how continued investment in combination innovation can deliver meaningful benefits for patients and healthcare systems.

Are new combinations trivial?

The case studies above illustrate that validated combination therapies are not simple repackaging of existing drugs. Developing a clinically meaningful combination requires identifying complementary mechanisms, determining safe and effective dose pairings, and evaluating how multiple medicines interact in the body when used together. These efforts often require additional clinical studies to confirm that the combination improves outcomes and performs reliably in clinical use.

For patients, these innovations can improve adherence to treatment plans, enhance efficacy, reduce side effects, and simplify long-term treatment. For healthcare systems, validated combinations can improve disease control and reduce complications. Combination therapies therefore represent a distinct and important form of post-approval innovation.

Why are there later-filed patents on new combination therapies? Do they block competition?

Because combination therapies are typically developed after the individual component medicines are approved, the research needed to create them occurs after those approvals. That work often involves solving new technical and clinical problems, such as identifying how multiple active medicines can be used together safely, determining appropriate dose combinations, and developing formulations that deliver consistent performance when drugs are combined.

When these challenges are successfully addressed, the resulting solutions may be patentable. These patents reflect new inventions arising from additional research, not extensions of earlier protections.

Patents on combination therapies do not prevent generic manufacturers from entering the market with generic versions of the original medicines once relevant patents expire. Generics can offer the component drugs separately, provided they are approved for individual use. Those generic products, however, do not replicate the clinically validated combination product, which is evaluated and used based on its performance as a combined therapy. Combination products therefore compete based on demonstrated clinical value, convenience, and patient preference. For a more detailed discussion of how post-approval patents relate to competition and generic entry, see our companion papers on evergreening and patent thickets.

Endnotes

1 This paper draws on desk research and interviews with scientific, regulatory, and IP teams at innovative biopharmaceutical companies. For product case studies, the timelines and scientific descriptions reflect publicly documented information, supplemented in some cases by interview context. Factual claims about approval dates, indications, and regulatory requirements were verified against publicly available FDA and EMA records. Information on clinical trials (including enrollment and outcomes) was checked through ClinicalTrials.gov entries and published trial results where available.

2 U.S. Food and Drug Administration. (2019). The History of FDA's Role in Preventing the Spread of HIV/AIDS, U.S. Food & Drug Administration. https://www.fda.gov/about-fda/fda-history-exhibits/history-fdas-role-preventing-spread-hivaids

3 Parienti, J. J., Bangsberg, D. R., Verdon, R., & Gardner, E. M. (2009). Better Adherence with Once-daily Antiretroviral Regimens: A Meta-Analysis. *Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America*, 48(4), 484–488. https://doi.org/10.1086/596482

4 Sax, P. E., Meyers, J. L., Mugavero, M., & Davis, K. L. (2012). Adherence to Antiretroviral Treatment and Correlation with Risk of Hospitalization Among Commercially Insured HIV Patients in the United States. *PLOS One*, 7(2), e31591. https://doi.org/10.1371/journal.pone.0031591; Bangsberg, D. R., Ragland, K., Monk, A., & Deeks, S. G. (2010). A single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV+ homeless and marginally housed people. *AIDS*, 24(18), 2835–2840. https://doi.org/10.1097/QAD.0b013e328340a209

5 Allemann, Y., Fraile, B., Lambert, M., Barbier, M., Ferber, P., & Izzo, J. L., Jr (2008). Efficacy of the Combination of Amlodipine and Valsartan in Patients with Hypertension Uncontrolled with Previous Monotherapy: The Exforge in Failure After Single Therapy (EX-FAST) Study. *Journal of Clinical Hypertension*, 10(3), 185–194. https://doi.org/10.1111/j.1751-7176.2008.07516.x